| Literature DB >> 30571792 |
Jorge Y P Palencia1, Alysson Saraiva2, Márvio Lobão Teixeira Abreu1, Marcio G Zangeronimo3, Allan P Schinckel4, Cesar Augusto Pospissil Garbossa5.
Abstract
The use of functional nutrients has been proposed to reduce the occurrence of intrauterine growth retardation in animals at birth in several mammalian species. The objective of this study was to verify the effectiveness of citrulline and N-carbamylglutamate (NCG) dietary supplementation as arginine precursors for mammalian species, and the effects on fetal development through a systematic review. The search for studies was performed during August 2018 in the PubMed, ISI Web of Science, Science Direct, and Scopus databases. The literature search was conducted using "arginine precursor", "citrulline", or "N-carbamylglutamate" as keywords, combined with "gestation", "pregnancy", "fetus", "newborn", or "reproduction". Studies in which arginine precursors were evaluated in gestating mammals and their effects on parameters related to the intrauterine development of the conceptus were selected. Of 1,379 articles, 18 were selected, primarily based on the title and the abstract. Supplementation with NCG (0.5 g to 2 g/kg of feed) increased maternal plasma arginine concentrations in all studies that evaluated this variable. Fetal number increased in 55.56% of the studies that evaluated it, and fetal weight increased in the majority (62.5%) of the studies evaluating this variable. By supplementing citrulline, only fetal weight was improved, with an increase in maternal plasma arginine in 40% of the studies. In conclusion, N-carbamoyl glutamate seems to be an arginine precursor more effective than L-citrulline during gestation; however, both precursors, beside L-Arginine, should be evaluated in similar conditions to confirm the existence of specific particularities such as periods and levels of supplementation, which need to be considered for different species of animals. The supplementation of NCG increases arginine concentrations in maternal plasma, thus improving mammalian reproductive efficiency and fetal development, mainly by promoting higher birth weight.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30571792 PMCID: PMC6301651 DOI: 10.1371/journal.pone.0209569
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1PRISMA diagram.
Preferred reporting items for systematic reviews and meta-analysis (PRISMA) flow diagram identifying the total number of articles initially surveyed, the number of articles included and excluded for this systematic review. From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PloS Med 6(7): e1000097. https://doi.org/10.1371/journal.pmed.1000097. For more information, visit www.prisma-statement.org.
Detailed results of the search in each database according to the keywords.
| Base | Search | Keywords | Total | ||
|---|---|---|---|---|---|
| 1 | 2 | 3 | |||
| Total number | 154 | 8 | 44 | 206 | |
| Selected number | 8 | 9 | 0 | 17 | |
| Duplicated number of selected papers | 0 | 0 | 1 | 1 | |
| Total number | 229 | 5 | 529 | 763 | |
| Selected number | 0 | 0 | 0 | 0 | |
| Duplicated number of selected papers | 1 | 1 | 1 | 3 | |
| Total number | 136 | 9 | 70 | 47 | |
| Selected number | 0 | 1 | 0 | 0 | |
| Duplicated number of selected papers | 8 | 8 | 1 | 17 | |
| Total number | 140 | 8 | 47 | 195 | |
| Selected number | 0 | 0 | 0 | 0 | |
| Duplicated number of selected papers | 8 | 10 | 2 | 20 | |
*1. Citrulline;
2. N-carbamylglutamate; 3. Arginine precursor and its combinations with the following words: Reproduction, gestation, pregnancy, fetus, and newborn.
†Final number of selected articles.
Summary of the general data of selected studies to evaluate the effectiveness of arginine precursors during gestation.
| # | Author | Species | Control dams | Supplemented dams | Supplementation form | Dosage | Supplementation period | Day of collection | Evaluated parameters |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Bourdon et al. (2016) [ | Rat | 8 to 10 | 8 to 10 | Water | 2 g/Kg BW/day | 7 to 21 days of gestation | 21 days of gestation | Water and feed intake, maternal weight gain, offspring size and fetal weight, placental weight, fetal and maternal plasma concentration of valine and alanine. Maternal plasma concentration of amino acids. Assessment of tissue protein synthesis; Assessment of urine. Placental gene expression. |
| 2 | Tran et al. (2016) [ | Rat | 3 to 4 | 3 to 4 | Water | 2 g/Kg BW/day | 2–15 and 2–21 of gestation | 15 and 21 days of gestation | Feed intake, fetal and placental weight, placental efficiency, placental morphometry, placental gene expression. |
| 3 | Tain et al. (2015) [ | Rat | 3 | 3 | Water | 2.5 g/L of water | Gestation and lactation | 12 weeks of life of male offspring | Weight at 3 months of age, heart and kidney weight, systolic blood pressure; Plasma creatinine concentration, determination of urinary excretion of cyclic guanosine monophosphate; kidney and plasma concentration of amino acids; protein determination, enzymatic activity and gene expression in kidney tissue. |
| 4 | Tain et al. (2014a) [ | Rat | NE | NE | Water | 2.5 g/L of water | Gestation and lactation | 12 weeks of life of male offspring | Weight at 3 months of age, body weight and organ function parameters; transcriptome and gene expression in kidney tissue. |
| 5 | Tain et al. (2014b) [ | Rat | NE | NE | Water | 2.5 g/L of water | Gestation and lactation | 16 weeks of age | Blood pressure, plasma concentration of amino acids and metabolites. Expression of proteins and genes in kidney tissue; mortality, live weight, kidney weight. |
| 6 | Tain et al. (2010) [ | Rat | NE | NE | Water | 2.5 g/L of water | Gestation and lactation | 25, 56 and 84 days after birth and 12 weeks of age | weight, blood pressure, urine collection, renal histology; plasma and tissue concentration of amino acids, enzymatic activity, expression of gene proteins in kidney tissue. |
| 7 | Lassala et al. (2009) [ | Goat | 6 | 6 | IV | 155 μmol/kg of BW | 130 days of gestation | 130 days of gestation | Determination of maternal and fetal plasma concentration of amino acids. |
| 8 | Koeners et al. (2007) [ | Rat | 6 | 6 | Water | 2.5 g/L of water | Gestation and lactation | At birth and two days of age | Concentration of renal and cardiac nitric oxide; renal gene expression; concentration of amino acids: arginine and citrulline; birth weight; blood pressure and renal function. |
| 9 | Cai et al. (2018) [ | Swine | 18 | 18 | Feed | 0.5 g/kg of feed | 1–8 days of gestation | At birth | Live weight (0 and 28 days of gestation); reproductive performance; blood collection for determination of serum metabolites and amino acids, metabolomic profiles in serum and amniotic fluid; protein abundance in the endometrium, fetuses, and placentae; expression levels of PGRMC1, lamin A/C, eNOS, and vimentin). |
| 9 | Cai et al. (2018) [ | Swine | 18 | 19 | Feed | 0.5 g/kg of feed | 9–28 days of gestation | At birth | Live weight (0 and 28 days of gestation); reproductive performance; blood collection for determination of serum metabolites and amino acids, metabolomic profiles in serum and amniotic fluid; protein abundance in the endometrium, fetuses, and placentae; expression levels of PGRMC1, lamin A/C, eNOS, and vimentin). |
| 9 | Cai et al. (2018) [ | Swine | 18 | 17 | Feed | 0.5 g/kg of feed | 1–28 days of gestation | At birth | Live weight (0 and 28 days of gestation); reproductive performance; blood collection for determination of serum metabolites and amino acids, metabolomic profiles in serum and amniotic fluid; protein abundance in the endometrium, fetuses, and placentae; expression levels of PGRMC1, lamin A/C, eNOS, and vimentin). |
| 10 | Sun et al. (2018) [ | Sheep | 8 | 8 | Feed | 5 g/day | 35–110 days of gestation | 110 days of gestation | Female and fetal weight; fetal organ weight; fetal plasma metabolite and hormone concentrations; amino acid concentrations in the fetal liver, amino acid concentrations of fetal longissimus dorsi muscle and expression of genes of the somatotropic axis. |
| 11 | Sun et al. (2017) [ | Sheep | 8 | 8 | Feed | 5 g / day | 35–110 days of gestation | 110 days of gestation | Female weight, fetal, and placentome weight and magnetic resonance of the blood plasma for assessment of 36 metabolites. |
| 12 | Zhang et al. (2016a) [ | Sheep | 8 | 8 | Feed | 5 g/day | 35–110 days of gestation | 110 days of gestation | Female weight, maternal organ weight, fetal organ weight and placentome size; serum concentrations of metabolites and hormones; amino acid concentrations in maternal artery, fetal umbilical vein, and in fetal fluids; concentration of polyamines in maternal, fetal, and placental fluids. |
| 13 | Zhang et al. (2016b) [ | Sheep | 8 | 8 | Feed | 5 g/day | 35–110 days of gestation | 110 days of gestation | Fetal weight; type, number, and average weight of placentomes; total weight and number of placentomes; antioxidant capacity in the maternal and fetal plasma and in the types of placentomes; concentration of mRNA of selected angiogenic and vasoactive factors and their receptors in placentomes; concentrations of metabolites and hormones. |
| 14 | Zhu et al. (2015) [ | Swine | 16 | 16 | Feed | 1.1 g/day | 1 to 28 days of gestation | 28 days of gestation | Maternal weight, number of total and living fetuses; number of corpora lutea; embryonic mortality; uterine weight; weight of viable fetuses and placenta, volume of amniotic fluid; glutamate, ornithine, arginine, and proline concentrations, NO, estradiol and progesterone in maternal plasma at 14 and 28 days of age; protein and gene expression of the endometrium. |
| 15 | Zhang et al. (2014) [ | Swine | 9 | 9/9/9/9 | Feed | 0.5, 1.0, 1.5, and 2.0 g/kg of feed | Throughout gestation | Birth | Live weight and backfat thickness (0, 30 and 110 days of gestation); blood collection for determination of amino acids, angiogenic factors and metabolites (30, 60, 90, and 110 days of gestation); weight of piglets at birth, live-born, stillbirths, and mummified, placental weight. chorioallantoic membrane sample for evaluation of gene expression (at birth). |
| 16 | Liu et al. (2012) [ | Swine | 9 | 9 | Feed | 1 g/kg of feed | Throughout gestation | 110 days of gestation and at birth | Number of births, birth weight, individual birth weight, classification as live-born, stillbirth, or mummified, plasma concentration of hormones, metabolites, and amino acids. Gene expression in the umbilical vein. |
| 17 | Zeng et al. (2012) [ | Rats | 12 | 12 | Feed | 1 g/kg of feed | Day 1 to 4 of gestation | Day 7 and 15 | Administration of antibody LIF (mTOR inhibitor); assessment of fetal weight, concept, placenta, and number of live fetuses |
| 17 | Zeng et al. (2012) [ | Rats | 15 | 15 | Feed | 1 g/kg of feed | Day 1 to 4 of gestation | Day 5 (slaughter) | Blood and uterine fluid to assess concentrations of amino acids and metabolites. |
| 17 | Zeng et al. (2012) [ | Rats | 96 | 96/96 | Feed | 0.5 and 1 g/kg of feed | Throughout gestation | Birth | Number of births, birth weight, individual birth weight, mortality, and sex. |
| 18 | Wu et al. (2012) [ | Swine | 9 | 9 | Feed | 1 g/kg of feed | Throughout gestation | 110 days of gestation and at birth | Blood for analysis of metabolites, minerals, hormones, and amino acids. Number of births, birth weight, live-born. Gene expression of the umbilical vein (at birth). |
NE: unspecified; IV: intravenous
Quality of the selected articles considering the selected criteria.
| Author/Year | A | B | C | D | E | F | G | H | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bourdon et al. (2016) [ | 2 | 2 | 1 | 2 | 2 | 1 | 1 | 2 | |
| Tran et al. (2016) [ | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 2 | |
| Tain et al. (2015) [ | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | |
| Tain et al. (2014a) [ | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | |
| Tain et al. (2014b) [ | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | |
| Tain et al. (2010) [ | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | |
| Lassala et al. (2009) [ | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | |
| Koeners et al. (2007) [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | |
| Cai et al. (2018) [ | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | |
| Sun et al. (2018) [ | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | |
| Sun et al. (2017) [ | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | |
| Zhang et al. (2016a) [ | 2 | 2 | 1 | 2 | 1 | 1 | 2 | 1 | |
| Zhang et al. (2016b) [ | 2 | 2 | 1 | 2 | 1 | 1 | 2 | 2 | |
| Zhu et al. (2015) [ | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | |
| Zhang et al. (2014) [ | 1 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | |
| Liu et al. (2012) [ | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | |
| Zeng et al. (2012) [ | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 2 | |
| Wu et al. (2012) [ | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
A. Randomization: 2 for randomized studies and 1 for non-randomized studies or no clarification of this aspect in the text;
B. Control group: 2 for studies that used a control group and 1 for studies that used no control group or did not clarify this in the text;
C. Sample size: 2 for studies that used more than 10 replicates per treatment and 1 for studies that used 10 or less replicates per treatment;
D. Environment characterization: 2 for studies that evaluated environmental parameters and 1 when this was not mentioned or not clear at the text;
E. Isonitrogenous diets: 2 for studies that used isonitrogenous diets and 1 for studies that did not use such diets are did not specify this in the text;
F. Different dosages: 2 for studies that used two or more levels of the precursor and 1 for studies that used only one level;
G. Parity order: 2 for studies that mentioned if the parity order of the dams was controlled and 1 for studies that did not mention this;
H. Molecular analysis: 2 for trials that used molecular analysis to explain the results and 1 for studies that did not use such analyses.
Supplementation effects of citrulline and N-carbamylglutamate for gestating mammals, compared to the control group, on reproductive performance parameters.
| Author/Year | Dose | Placental | Fetuses | Live fetuses | Weight fetuses | Weight of viable fetuses | Mortality | Benefits |
|---|---|---|---|---|---|---|---|---|
| Bourdon et al. (2016) [ | 2 g/kg of BW | NS | NS | NE | 8.64% | NE | NE | YES |
| Tran et al. (2016) (Day 15) [ | 2 g/ kg of BW | NS | NE | NE | NS | NE | NE | IND |
| Tran et al. (2016) (Day 21) [ | 2 g/ kg of BW | NS | NE | NE | 4.00% | NE | NE | YES |
| Tain et al. (2015) [ | 2.5 g/L of water | NE | NS | NE | NS | NE | NS | IND |
| Tain et al. (2014a) [ | 2.5 g/L of water | NE | NS | NE | NS | NE | NS | IND |
| Tain et al. (2014b) [ | 2.5 g/L of water | NE | NE | NE | NE | NE | NE | NE |
| Tain et al. (2010) [ | 2.5 g/L of water | NE | NE | NE | NE | NE | NE | NE |
| Lassala et al. (2009) [ | 2.5 g/L of water | NE | NE | NE | NE | NE | NE | NE |
| Koerners et al. (2007) [ | 155 micromol/kg of BW | NE | NE | NE | NE | NE | NE | NE |
| Cai et al. (2018) [ | 0.5 g/kg (1–8 days) | NE | NS | NS | NE | NS | NS | IND |
| 0.5 g/kg (9–28 days) | NE | NS | 8.12% | NE | NS | NS | YES | |
| 0.5 g/kg (1–28 days) | NE | 9.63% | 11.34% | NE | NS | NS | YES | |
| Sun et al. (2018) [ | 5g/day | NE | NE | NE | NE | ↑ | NE | YES |
| Sun et al. (2017) [ | 5g/day | NS | NE | NE | 20.00% | NE | NE | YES |
| Zhang et al. (2016a) [ | 5g/day | NS | NE | NE | 20.10% | NE | NE | YES |
| Zhang et al. (2016b) [ | 5g/day | NS | NE | NE | 19.15% | NE | NE | YES |
| Zhu et al. (2015) [ | 1.1 g/day | 12.87% | 11.50% | 11.82% | NE | 17.98% | -51.53% | YES |
| Zhang et al. (2014) [ | 0.5 g/kg of ration | 14.62% | NS | NS | 6.57% | 19.17% | NS | YES |
| Liu et al. (2012) [ | 1 g/kg of ration | NE | NS | NS | NS | 13.60% | -61.11% | YES |
| Zeng et al. (2012) [ | 1 g/kg of ration | NE | 6.90% | 7.02% | NS | 6.75% | NE | YES |
| 0.5 g/kg of ration | NE | 12.93% | 14.04% | NS | 14.05% | NE | YES | |
| Wu et al. (2012) [ | 1 g/kg of ration | NE | NS | NS | 8.90% | NE | NE | YES |
NS: not significant; NE: not evaluated; IND: indifferent; ↑: increase
Supplementation effects of citrulline and N-carbamylglutamate for gestating mammals on plasmatic or tissue amino acid concentrations.
| Reference | Evaluated material | Amino acids | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arginine | Proline | Ornithine | Citrulline | Aspartate | Glutamate | Glutamine | Alanine | NCG | ADMA | SDMA | Profiles of other AAs | ||
| Bourdon et al. (2016) [ | Plasmatic | 115.00% | NE | 280.00% | 360.00% | NE | NE | NE | NE | NE | NE | NE | NE |
| Tran et al. (2016) [ | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Tain et al. (2015) [ | Plasmatic | NS | NE | NE | NS | NE | NE | NE | NE | NE | NS | NS | NE |
| Tain et al. (2014a) [ | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Tain et al. (2014b) [ | NE | NS | NE | NE | NS | NE | NE | NE | NE | NE | NS | NS | NE |
| Tain et al. (2010) [ | Plasmatic | 31.00% | NE | NE | NS | NE | NE | NE | NE | NE | -3.33% | 3.77% | NE |
| Lassala et al. (2009) [ | Maternal | ↑ | NE | NS | ↑ | NE | NE | NE | NE | NE | NE | NE | NE |
| Fetal | ↑ | ↑ | ↑ | ↑ | NE | NE | NE | NE | NE | NE | NE | NE | |
| Koerners et al. (2007) [ | Female—heart | 1.15% | NE | NS | NS | NE | NE | NE | NE | NE | NE | NE | NS |
| Female—kidney | NS | NE | NS | NS | NE | NE | NE | NE | NE | NE | NE | NS | |
| Male—heart | -5.06% | NE | -19.35% | NS | NE | NE | NE | NE | NE | NE | NE | NS | |
| Male—kidney | NS | NE | NS | NS | NE | NE | NE | NE | NE | NE | NE | NS | |
| Cai et al. (2018) [ | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Sun et al. (2018) [ | Fetal liver | NS | 45.23% | 26.84% | 24.70% | 37.72% | 26.38% | 12.97% | NS | NE | NE | NE | YES |
| Fetal | 72.51% | NS | NS | 11.19% | 33.89% | 21.95% | 15.40% | 18.81% | NE | NE | NE | YES | |
| Sun et al. (2017) [ | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Zhang et al. (2016a) [ | Plasmatic | 50.84% | 52.24% | 44.00% | 32.24% | 46.34% | NS | NS | 46.40% | NE | NE | NE | YES |
| Zhang et al. (2016b) [ | Plasmatic | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Zhu et al. (2015) [ | Plasmatic | 30.21% | 14.44% | 43.33% | NE | NE | 16.86% | NE | NE | NE | NE | NE | NE |
| 38.97% | 17.20% | 23.85% | NE | NE | 41.18% | NE | NE | NE | NE | NE | NE | ||
| Zhang et al. (2014) [ | Plasmatic | 11.97% | -7.35% | 13.29% | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Plasmatic | 8.99% | -7.79% | 14.86% | NE | NE | NE | NE | NE | NE | NE | NE | NE | |
| Plasmatic | 8.64% | -8.56% | 17.80% | NE | NE | NE | NE | NE | NE | NE | NE | NE | |
| Plasmatic | NS | -8.33% | 15.05% | NE | NE | NE | NE | NE | NE | NE | NE | NE | |
| Liu et al. (2012) [ | Plasmatic | 40.63% | -46.67% | NE | NE | 5% | NE | NS | NE | NE | NE | NE | NE |
| Wu et al. (2012) [ | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Zeng et al. (2012) [ | Plasmatic | 49.16% | 20.36% | 69.66% | NE | NE | NS | NS | NE | NE | NE | NE | NE |
| Uterine fluid | 18.77% | 139.35% | NS | NE | NE | 34.15% | 49.56% | NE | NE | NE | NE | NE | |
SDMA: symmetric dimethylarginine;
ADMA: asymmetric dimethylarginine;
*AA concentration increase compared to the control group;
† Profile change of the other AA;
†† Changed: Methionine (50.00%), Isoleucine (30.16%), Leucine (33.33%), Cysteine (38.30%).
††† Changed: Lysine (23.30%), Methionine (63.14%), Phenylalanine (31.28%), Threonine (43.08%), Tryptophan (37.24%), Tyrosine (54.28%).
††††. Changed: Isoleucine (21.70%), Leucine (28.70%), Lysine (18.94), Methionine (35.58%), Phenylalanine (42.90%), Threonine (28.72%), Valine (24.76%), Asparagine (30.67%), Glycine (-51.36%).
NS: not significant; NE: not evaluated; ↑: increase
Fig 2Metabolic pathways of arginine precursors conversion to arginine.
Adapted from [53].